Medtronic agrees to settle with Boston over stent lawsuits
This article was originally published in Clinica
Executive Summary
Medtronic agreed this week to pay Boston Scientific the $175m which an arbitration panel last year said the Minneapolis company should do for infringing certain Boston stent patents. The award, of $169m plus costs and injunction fees (see Clinica No 967, p 13), was never paid however, and the companies has continued negotiations since then.
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.